Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial

被引：0
|
作者：
Fizazi, K. [1 ]
Mella, P. Gonzalez
Castellano, D.
Minatta, J. N.
Kalebasty, A. R.
Shaffer, D.
Limon, J. C. Vazquez
Lopez, H. M. Sanchez
Armstrong, A. J.
Horvath, L.
Bastos, D. A.
Amin, N. P.
Li, J.
Unsal-Kacmaz, K.
Retz, M.
Saad, F.
Petrylak, D. P.
Pachynski, R. K.
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
D O I：
10.1097/JU.0000000000003046
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：445 / 446
页数：2
相关论文
共 50 条
  • [1] CheckMate 9KD Arm B Final Analysis: Efficacy and Safety of Nivolumab Plus Docetaxel for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 10 - 11
  • [2] Nivolumab plus docetaxel in patients with chemotherapy- nai spacing diaeresis ve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
    Fizazi, Karim
    Gonzalez Mella, Pablo
    Castellano, Daniel
    Minatta, Jose N.
    Rezazadeh Kalebasty, Arash
    Shaffer, David
    Vazquez Limon, Juan C.
    Sanchez Lopez, Hector M.
    Armstrong, Andrew J.
    Horvath, Lisa
    Bastos, Diogo A.
    Amin, Neha P.
    Li, Jia
    Unsal-Kacmaz, Keziban
    Retz, Margitta
    Saad, Fred
    Petrylak, Daniel P.
    Pachynski, Russell K.
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 61 - 71
  • [3] Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
    Fizazi, Karim
    Retz, Margitta
    Petrylak, Daniel P.
    Goh, Jeffrey C.
    Perez-Gracia, Jose
    Lacombe, Louis
    Zschabitz, Stefanie
    Burotto, Mauricio
    Mahammedi, Hakim
    Gravis, Gwenaelle
    Bastos, Diogo Assed
    McCune, Steven L.
    Limon, Juan Carlos Vazquez
    Kwan, Edmond M.
    Castellano, Daniel
    Flechon, Aude
    Saad, Fred
    Grimm, Marc-Oliver
    Shaffer, David R.
    Armstrong, Andrew J.
    Bhagavatheeswaran, Prabhu
    Amin, Neha P.
    Unsal-Kacmaz, Keziban
    Wang, Xuya
    Li, Jun
    Loehr, Andrea
    Pachynski, Russell K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [4] CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer.
    Fizazi, Karim
    Mella, Pablo Gonzalez
    Castellano, Daniel
    Minatta, Jose Nicolas
    Rezazadeh, Arash
    Shaffer, David R.
    Vazquez Limon, Juan Carlos
    Sanchez Lopez, Hector Manuel
    Armstrong, Andrew J.
    Horvath, Lisa
    Dzik, Carlos
    Amin, Neha P.
    Li Jia
    Unsal-Kacmaz, Keziban
    Retz, Margitta
    Saad, Fred
    Petrylak, Daniel Peter
    Pachynski, Russell Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
    Fizazi, K.
    Gonzalez Mella, P.
    Castellano, D.
    Minatta, N.
    Kalebasty, A. Rezazadeh
    Shaffer, D.
    Vazquez Limon, J. C.
    Armstrong, A. J.
    Sanchez Lopez, H. M.
    Sharkey, B.
    Saci, A.
    Li, J.
    Wang, X.
    Ciprotti, M.
    Sathyanarayana, P.
    Saad, F.
    Petrylak, D. P.
    Retz, M. M.
    Pachynski, R. K.
    Drake, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) plus rucaparib for chemotherapy (CT)-naive metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Perez-Gracia, J. L.
    Lacombe, L.
    Bastos, D. A.
    Mahammedi, H.
    Kwan, E. M.
    Zschaeitz, S.
    Armstrong, A. J.
    Pachynski, R. K.
    Goh, J. C.
    Burotto, M.
    Gravis, G.
    McCune, S. L.
    Vazquez Limon, J. C.
    Retz, M.
    Saad, F.
    Amin, N. P.
    Li, J.
    Unsal-Kacmaz, K.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S629 - S630
  • [7] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (CheckMate 9KD)
    Gruellich, C.
    Fizazi, K.
    Drake, C.
    Shaffer, D.
    Pachynski, R.
    Saad, F.
    Ciprotti, M.
    Kong, G.
    Ryan, C.
    Petrylak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 323 - 323
  • [8] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
    Fizazi, Karim
    Drake, Charles G.
    Shaffer, David R.
    Pachynski, Russell
    Saad, Fred
    Ciprotti, Marika
    Kong, George
    Ryan, Charles J.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
    Pachynski, Russell Kent
    Retz, Margitta
    Goh, Jeffrey C.
    Burotto, Mauricio
    Gravis, Gwenaelle
    Castellano, Daniel
    Flechon, Aude
    Zschaebitz, Stefanie
    Shaffer, David R.
    Limon, Juan Carlos Vazquez
    Grimm, Marc-Oliver
    McCune, Steven L.
    Amin, Neha P.
    Li, Jia
    Wang, Xuya
    Unsal-Kacmaz, Keziban
    Saad, Fred
    Petrylak, Daniel P.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    Zurita, A. J.
    George, D. J.
    Shore, N. D.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Kozloff, M.
    Mathew, P.
    Harmon, C. S.
    Wang, S. L.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 688 - 694
12345